AU709498B2 - Improved adenoviral vectors and producer cells - Google Patents

Improved adenoviral vectors and producer cells Download PDF

Info

Publication number: AU709498B2
Authority: AU; Australia
Prior art keywords: adenoviral; vector; cell; promoter; dna sequence
Prior art date: 1994-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU45111/96A

Other languages

English (en)

Other versions

AU4511196A (en

Inventor

Mario Goziglia

Michael Kadan

Bruce Trapnell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genetic Therapy Inc

Original Assignee

Genetic Therapy Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-12

Filing date

1995-12-07

Publication date

1999-09-02

1995-12-07 Application filed by Genetic Therapy Inc filed Critical Genetic Therapy Inc

1996-07-03 Publication of AU4511196A publication Critical patent/AU4511196A/en

1999-09-02 Application granted granted Critical

1999-09-02 Publication of AU709498B2 publication Critical patent/AU709498B2/en

2015-12-07 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000013598 vector Substances 0.000 title claims description 214
230000001976 improved effect Effects 0.000 title description 6
210000004027 cell Anatomy 0.000 claims description 138
108090000623 proteins and genes Proteins 0.000 claims description 99
108091028043 Nucleic acid sequence Proteins 0.000 claims description 94
230000014509 gene expression Effects 0.000 claims description 48
230000001939 inductive effect Effects 0.000 claims description 39
102000004169 proteins and genes Human genes 0.000 claims description 39
108020004414 DNA Proteins 0.000 claims description 34
241000701161 unidentified adenovirus Species 0.000 claims description 34
230000006870 function Effects 0.000 claims description 33
238000004519 manufacturing process Methods 0.000 claims description 23
239000003814 drug Substances 0.000 claims description 19
229920001184 polypeptide Polymers 0.000 claims description 17
108090000765 processed proteins & peptides Proteins 0.000 claims description 17
102000004196 processed proteins & peptides Human genes 0.000 claims description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
239000003862 glucocorticoid Substances 0.000 claims description 13
238000000034 method Methods 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 11
210000003527 eukaryotic cell Anatomy 0.000 claims description 10
238000001415 gene therapy Methods 0.000 claims description 10
230000004853 protein function Effects 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
241000713333 Mouse mammary tumor virus Species 0.000 claims description 5
239000004098 Tetracycline Substances 0.000 claims description 3
230000002068 genetic effect Effects 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
229930101283 tetracycline Natural products 0.000 claims description 3
229960002180 tetracycline Drugs 0.000 claims description 3
235000019364 tetracycline Nutrition 0.000 claims description 3
150000003522 tetracyclines Chemical class 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 2
230000003115 biocidal effect Effects 0.000 claims 2
239000003242 anti bacterial agent Substances 0.000 claims 1
230000002463 transducing effect Effects 0.000 claims 1
239000013612 plasmid Substances 0.000 description 93
239000012634 fragment Substances 0.000 description 88
241001135569 Human adenovirus 5 Species 0.000 description 60
230000037430 deletion Effects 0.000 description 41
238000012217 deletion Methods 0.000 description 41
239000002245 particle Substances 0.000 description 32
238000010276 construction Methods 0.000 description 28
108700019146 Transgenes Proteins 0.000 description 27
241000700605 Viruses Species 0.000 description 22
208000015181 infectious disease Diseases 0.000 description 20
230000002458 infectious effect Effects 0.000 description 18
230000006801 homologous recombination Effects 0.000 description 16
238000002744 homologous recombination Methods 0.000 description 16
238000001890 transfection Methods 0.000 description 15
238000000338 in vitro Methods 0.000 description 14
229940124597 therapeutic agent Drugs 0.000 description 13
239000011543 agarose gel Substances 0.000 description 11
108700026244 Open Reading Frames Proteins 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
108700008625 Reporter Genes Proteins 0.000 description 9
230000001276 controlling effect Effects 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 7
108700005077 Viral Genes Proteins 0.000 description 7
210000005229 liver cell Anatomy 0.000 description 7
230000035772 mutation Effects 0.000 description 7
238000013459 approach Methods 0.000 description 6
238000005520 cutting process Methods 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
230000010076 replication Effects 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 5
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 5
230000004543 DNA replication Effects 0.000 description 5
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 5
108020004440 Thymidine kinase Proteins 0.000 description 5
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
229960003957 dexamethasone Drugs 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 4
108020005202 Viral DNA Proteins 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
230000000692 anti-sense effect Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000007547 defect Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
230000029812 viral genome replication Effects 0.000 description 4
108091026890 Coding region Proteins 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
108700039887 Essential Genes Proteins 0.000 description 3
101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 3
108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
102000056427 human CFTR Human genes 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
229950010131 puromycin Drugs 0.000 description 3
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
239000007858 starting material Substances 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
101150029409 CFTR gene Proteins 0.000 description 2
102100022641 Coagulation factor IX Human genes 0.000 description 2
206010010144 Completed suicide Diseases 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
108010076282 Factor IX Proteins 0.000 description 2
108010054218 Factor VIII Proteins 0.000 description 2
102000001690 Factor VIII Human genes 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
208000031220 Hemophilia Diseases 0.000 description 2
208000009292 Hemophilia A Diseases 0.000 description 2
206010019786 Hepatitis non-A non-B Diseases 0.000 description 2
101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
241000193096 Human adenovirus B3 Species 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
102100024407 Jouberin Human genes 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 2
102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 2
108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 2
108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 2
102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 2
102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 2
101150090155 R gene Proteins 0.000 description 2
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
230000004913 activation Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
230000002950 deficient Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
238000012869 ethanol precipitation Methods 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229960004222 factor ix Drugs 0.000 description 2
229960000301 factor viii Drugs 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
230000005745 host immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
101150066555 lacZ gene Proteins 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000001466 metabolic labeling Methods 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
108700026215 vpr Genes Proteins 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
102100036664 Adenosine deaminase Human genes 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
102000018655 Apolipoproteins C Human genes 0.000 description 1
108010027070 Apolipoproteins C Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
101000765604 Bacillus subtilis (strain 168) FlaA locus 22.9 kDa protein Proteins 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
101000964402 Caldicellulosiruptor saccharolyticus Uncharacterized protein in xynC 3'region Proteins 0.000 description 1
101000804668 Carnation latent virus RNA silencing suppressor Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
101150066038 E4 gene Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
101710192606 Latent membrane protein 2 Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
101000977779 Lymantria dispar multicapsid nuclear polyhedrosis virus Uncharacterized 33.9 kDa protein in PE 3'region Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
101000827630 Narcissus mosaic virus Uncharacterized 10 kDa protein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
201000011252 Phenylketonuria Diseases 0.000 description 1
101710132596 Protein E4 Proteins 0.000 description 1
208000008425 Protein deficiency Diseases 0.000 description 1
102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101710109576 Terminal protein Proteins 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
101900150902 Varicella-zoster virus Thymidine kinase Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003263 anti-adenoviral effect Effects 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000001842 enterocyte Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
229940097277 hygromycin b Drugs 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000005033 mesothelial cell Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000005937 nuclear translocation Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000003014 totipotent stem cell Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/70—Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Hematology (AREA)
Zoology (AREA)
Obesity (AREA)
Wood Science & Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Virology (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU45111/96A 1994-12-12 1995-12-07 Improved adenoviral vectors and producer cells Ceased AU709498B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US35508794A	1994-12-12	1994-12-12
US08/355087		1994-12-12
US45840395A	1995-06-02	1995-06-02
US08/458403		1995-06-02
PCT/US1995/015947 WO1996018418A1 (fr)	1994-12-12	1995-12-07	Vecteurs adenoviraux ameliores et cellules productrices

Publications (2)

Publication Number	Publication Date
AU4511196A AU4511196A (en)	1996-07-03
AU709498B2 true AU709498B2 (en)	1999-09-02

Family

ID=26998695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU45111/96A Ceased AU709498B2 (en)	1994-12-12	1995-12-07	Improved adenoviral vectors and producer cells

Country Status (6)

Country	Link
EP (1)	EP0797454A4 (fr)
JP (1)	JPH10510987A (fr)
AU (1)	AU709498B2 (fr)
CA (1)	CA2206683A1 (fr)
NZ (1)	NZ300387A (fr)
WO (1)	WO1996018418A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE336587T1 (de) *	1994-06-10	2006-09-15	Genvec Inc	Adenoviren-vektor systeme und zelllinien
DE69534166T2 (de) *	1994-10-28	2006-03-09	Trustees Of The University Of Pennsylvania	Rekombinanter adenovirus und methoden zu dessen verwendung
US6638762B1 (en)	1994-11-28	2003-10-28	Genetic Therapy, Inc.	Tissue-vectors specific replication and gene expression
US5998205A (en) *	1994-11-28	1999-12-07	Genetic Therapy, Inc.	Vectors for tissue-specific replication
IL116816A (en) *	1995-01-20	2003-05-29	Rhone Poulenc Rorer Sa	Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5872154A (en) *	1995-02-24	1999-02-16	The Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant adenovirus
US6251957B1 (en)	1995-02-24	2001-06-26	Trustees Of The University Of Pennsylvania	Method of reducing an immune response to a recombinant virus
US5756283A (en) *	1995-06-05	1998-05-26	The Trustees Of The University Of Pennsylvania	Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en)	1995-06-05	2001-08-28	The Trustees Of The University Of Pennsylvania	Adenovirus gene therapy vehicle and cell line
US6265212B1 (en)	1995-06-15	2001-07-24	Introgene B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en)	1995-06-15	2004-07-25	Crucell Holland Bv	A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998032860A1 (fr) *	1997-01-28	1998-07-30	Baxter International Inc.	Procede de production a haut rendement de vecteurs adenoviraux
US6403370B1 (en)	1997-02-10	2002-06-11	Genstar Therapeutics Corporation	Oncolytic/immunogenic complementary-adenoviral vector system
WO1998059063A2 (fr) *	1997-06-23	1998-12-30	University Of Saskatchewan	Genome de l'adenovirus bovin de type 3
US6670188B1 (en)	1998-04-24	2003-12-30	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
US6682929B2 (en)	2001-07-23	2004-01-27	Genvec, Inc.	Adenovector complementing cells
US20030158112A1 (en)	2002-02-15	2003-08-21	Johns Hopkins University School Of Medicine	Selective induction of apoptosis to treat ocular disease
US7364727B2 (en)	2002-07-22	2008-04-29	Cell Genesys, Inc.	Metastatic colon cancer specific promoter and uses thereof
US7977049B2 (en)	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (fr)	2002-08-09	2004-02-09	President And Fellows Of Harvard College	Methodes et compositions pour prolonger la duree de vie et accroitre la resistance au stress de cellules et d'organismes
US7026164B2 (en)	2003-07-03	2006-04-11	Cell Genesys, Inc.	Adenovirus packaging cell lines
CN1863918B (zh)	2003-10-02	2011-03-30	克鲁塞尔荷兰公司	用于重组腺病毒的包装细胞
CN103237889B (zh)	2010-08-16	2017-04-05	萨克生物研究学院	腺病毒组装方法
SG11201507393TA (en)	2013-03-14	2015-10-29	Salk Inst For Biological Studi	Oncolytic adenovirus compositions
EP3188762A4 (fr)	2014-07-31	2018-01-10	The Board of Regents of the University of Oklahoma	Mutants de rpe65 de mammifère à activité isomérohydrolase élevée
KR102608590B1 (ko)	2014-09-24	2023-12-01	솔크 인스티튜트 포 바이올로지칼 스터디즈	종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (fr)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Dosage à haut débit pour mesurer la cinétique de réplication d'un adénovirus
WO2017147269A1 (fr)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Expression de gènes exogènes dans un adénovirus thérapeutique pour un effet minimal sur la cinétique virale
EP3532082A4 (fr)	2016-12-12	2020-08-26	Salk Institute for Biological Studies	Adénovirus synthétiques ciblant une tumeur et leurs utilisations
CN112292449A (zh)	2018-04-09	2021-01-29	萨克生物研究学院	具有增强的复制特性的溶瘤腺病毒组合物
MX2021014525A (es) *	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994012649A2 (fr) *	1992-12-03	1994-06-09	Genzyme Corporation	Therapie genique de la fibrose kystique
WO1994028152A1 (fr) *	1993-05-28	1994-12-08	Transgene S.A.	Adenovirus defectifs et lignees de complementation correspondantes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0710288B1 (fr) *	1993-06-10	2006-04-05	Genetic Therapy, Inc.	Vecteurs adenoviraux pour le traitement de l'hemophilie
ATE336587T1 (de) *	1994-06-10	2006-09-15	Genvec Inc	Adenoviren-vektor systeme und zelllinien
FR2724945B1 (fr) *	1994-09-27	1996-12-27	Centre Nat Rech Scient	Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) *	1994-10-28	1996-11-29	Centre Nat Rech Scient	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) *	1994-11-03	1999-02-16	Cell Genesys Inc.	Packaging cell lines for adeno-associated viral vectors

1995
- 1995-12-07 WO PCT/US1995/015947 patent/WO1996018418A1/fr not_active Ceased
- 1995-12-07 CA CA002206683A patent/CA2206683A1/fr not_active Abandoned
- 1995-12-07 JP JP8519157A patent/JPH10510987A/ja active Pending
- 1995-12-07 EP EP95943705A patent/EP0797454A4/fr not_active Withdrawn
- 1995-12-07 AU AU45111/96A patent/AU709498B2/en not_active Ceased
- 1995-12-07 NZ NZ300387A patent/NZ300387A/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994012649A2 (fr) *	1992-12-03	1994-06-09	Genzyme Corporation	Therapie genique de la fibrose kystique
WO1994028152A1 (fr) *	1993-05-28	1994-12-08	Transgene S.A.	Adenovirus defectifs et lignees de complementation correspondantes

Also Published As

Publication number	Publication date
AU4511196A (en)	1996-07-03
WO1996018418A1 (fr)	1996-06-20
NZ300387A (en)	2001-07-27
JPH10510987A (ja)	1998-10-27
CA2206683A1 (fr)	1996-06-20
EP0797454A4 (fr)	2001-12-05
EP0797454A1 (fr)	1997-10-01

Legal Events

Date	Code	Title	Description
2004-07-08	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Publication	Publication Date	Title
AU709498B2 (en)	1999-09-02	Improved adenoviral vectors and producer cells
US6156497A (en)	2000-12-05	Recombinase-mediated generation of adenoviral vectors
AU735806B2 (en)	2001-07-19	Adenoviruses having altered hexon proteins
EP1032696B1 (fr)	2006-06-14	Vecteur pour replication et expression genique a specificite tissulaire
Lieber et al.	1996	Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo
EP0870049B1 (fr)	2006-03-15	Systemes de vecteurs adenoviraux et de lignees cellulaires complementaires
WO1997025446A9 (fr)	1997-10-09	Generation de vecteurs adenoviraux a mediation de recombinase
CA2206179C (fr)	2007-10-23	Vecteurs de replication a specificite tissulaire
JP3565859B2 (ja)	2004-09-15	改良されたアデノウイルスおよびその使用法
US20080103109A1 (en)	2008-05-01	Vectors for tissue-specific replication
WO1996017053A9 (fr)	1996-07-25	Vecteurs de replication a specificite tissulaire
JP2000106875A (ja)	2000-04-18	目的遺伝子の発現を改善するためのアデノウイルスｅ４リ―ディングフレ―ムの使用
US20020019051A1 (en)	2002-02-14	Chimeric adenoviral vectors
Zhang	1997	Adenoviral vectors: development and application
AU3345801A (en)	2001-06-21	Recombinase-mediated generation of adenoviral vectors